oxitropium: RN given refers to bromide; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6917866 |
| CHEMBL ID | 4297364 |
| CHEBI ID | 135418 |
| MeSH ID | M0068480 |
| Synonym |
|---|
| oxitropium |
| CHEBI:135418 |
| 8g15t83e6i , |
| (7(s)-(1alpha,2beta,4beta,5alpha,7beta))-9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane |
| unii-8g15t83e6i |
| 99571-64-9 |
| (8r)-6beta,7beta-epoxy-8-ethyl-3alpha-hydroxy-1alphah,5alphah-tropanium (-)-tropate. |
| (8r)-6.beta.,7.beta.-epoxy-8-ethyl-3.alpha.-hydroxy-1.alpha.h,5.alpha.h-tropanium (-)-tropate. |
| (7(s)-(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.))-9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane |
| oxitropium [who-dd] |
| DTXSID9048144 |
| DB12086 |
| [(1s,2s,4r,5r)-9-ethyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2s)-3-hydroxy-2-phenylpropanoate |
| Q27270351 |
| CHEMBL4297364 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Any adverse event occurring during the treatment period was recorded on a diary card." | ( Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). Bellia, V; Bensi, G; Bianco, S; Foresi, A; Grassi, V; Olivieri, D; Volonté, M, 2002) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The only pharmacokinetic data were obtained with the 14C-labelled compound." | ( Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. Cornelissen, PJ; de Zeeuw, RA; Ensing, K; in 't Hout, WG, 1989) | 0.28 |
| " The active ingredient which can be separated from the metabolites by thin layer chromatography and quantified via the radioactivity reaches a maximum in the rat plasma after 1 to 2 h; it is then eliminated from the blood with a half-life of approx." | ( [Biochemical studies with oxitropium bromide. 1. Pharmacokinetics and metabolism in the rat and dog]. Förster, HJ; Pook, KH; Richter, I; Wahl, D, 1985) | 0.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Those in approved clinical use are synthetic quaternary ammonium congeners of atropine, and include ipratropium bromide, oxitropium bromide, and tiotropium bromide, each of which is very poorly absorbed when given by inhalation." | ( Anticholinergic agents in asthma and COPD. Gross, NJ, 2006) | 0.33 |
Twenty-four elderly male patients with moderate-to-severe chronic airway obstruction took part in a double-blind, placebo-controlled, randomized dose-response and response-duration comparison. No significant difference was noticed between results obtained with either act.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This was associated with airway beta-adrenoceptor blockade as demonstrated by a shift in the isoproterenol dose-response curve." | ( Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Barnes, PJ; Dixon, CM; Fuller, RW; Ind, PW, 1989) | 0.28 |
| " No significant difference was noticed between results obtained with either active drug, as well as with either dosage of oxitropium." | ( Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma. Bellia, V; Cibella, F; Cuttitta, G; Ferrara, G; Insalaco, G; Mirto, M; Peralta, G; Visconti, A, 1988) | 0.27 |
| "Twenty-four elderly male patients with moderate-to-severe chronic airway obstruction took part in a double-blind, placebo-controlled, randomized dose-response and response-duration comparison of a new inhaled anticholinergic bronchodilator oxitropium bromide and the inhaled beta-agonist bronchodilator fenoterol hydrobromide." | ( Effects of inhaled oxitropium and fenoterol, alone and in combination, in chronic airflow obstruction. Atkinson, J; Frith, PA; Jenner, B, 1986) | 0.27 |
| " The results suggest that enhancement of the early bronchodilator response obtained by adding oxitropium bromide to a conventional dose of salbutamol in patients with stable asthma reflects suboptimal dosing of salbutamol rather than differences between the agents in mechanisms of action, whereas enhancement in duration of response is related also to the pharmacological characteristics of oxitropium bromide." | ( Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols. Laitinen, LA; Poppius, H, 1986) | 0.27 |
| " The drop in FEV1 after administration of increasing doses of acetylcholine aerosol spray was measured 45 min after administration of the test drug, and the dose-response curve was determined." | ( [Effect of a new synthetic anticholinergic (oxytropium bromide) on acetylcholine-induced bronchospasm]. Auzerie, J; Fréour, P; Taytard, A; Vaida, P; Vergeret, J, 1983) | 0.27 |
| " An adaptation of the usual dosage should be considered." | ( Early bronchodilating effect of oxitropium bromide in comparison with ipratropium bromide. Delwiche, JP; Lulling, J; Prignot, J, 1981) | 0.26 |
| " However, dosage requirements have not been thoroughly evaluated and comparative dose-response data for these agents are limited." | ( Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Ikeda, A; Izumi, T; Koyama, H; Nishimura, K, 1995) | 0.29 |
| " The cumulative dose-response curve of oxitropium bromide inhaled from a metered-dose inhaler was determined in eleven normal subjects." | ( Bronchodilator effects of oxitropium bromide, fenoterol, and their combination in normal subjects. Fujimura, M; Hashimoto, T; Kamio, Y; Matsuda, T, 1993) | 0.29 |
| "We examined whether a pretreatment with formoterol, oxitropium bromide, or salmeterol might modify the dose-response curves to inhaled salbutamol in patients with stable and partially reversible chronic obstructive pulmonary disease (COPD)." | ( Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Calderaro, F; Cazzola, M; Di Perna, F; Girbino, G; Matera, MG; Noschese, P; Vinciguerra, A, 1998) | 0.3 |
| " Two hours after inhalation a dose-response curve to inhaled oxitropium bromide (100 microg/puff) or placebo was constructed using one puff, one puff, two puffs, and two puffs-that is, a total cumulative dose of 600 microg oxitropium bromide." | ( Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Califano, C; Cazzola, M; Centanni, S; D'Amato, G; D'Amato, M; Di Perna, F; Donner, CF, 1999) | 0.3 |
| "This study shows that acute pretreatment with 50 microg salmeterol does not block the possibility of inducing more bronchodilation with an anticholinergic agent when a higher than normal dosage of the muscarinic antagonist is used." | ( Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Califano, C; Cazzola, M; Centanni, S; D'Amato, G; D'Amato, M; Di Perna, F; Donner, CF, 1999) | 0.3 |
| " Two hours after inhalation, a dose-response curve to inhaled oxitropium bromide (100 microg puff(-1)) or placebo was constructed using one puff, one puff, two puffs and two puffs, for a total cumulative dose of 600 microg oxitropium bromide." | ( Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Califano, C; Cazzola, M; D'Amato, M; Di Perna, E; Matera, MG; Mazzarella, G, 1999) | 0.3 |
| " Also, the dose-response slope (decline percentage of FEV(1)/cumulative methacholine dose) after PD(15) was similar in both OXI and TIO groups but different in the IB group." | ( Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma. Antonio, C; Barzan, R; Bruno, S; Calabrese, A; Clemente, F; Franco, C; Roberta, B; Sposato, B, 2008) | 0.35 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 42 (35.29) | 18.7374 |
| 1990's | 47 (39.50) | 18.2507 |
| 2000's | 21 (17.65) | 29.6817 |
| 2010's | 8 (6.72) | 24.3611 |
| 2020's | 1 (0.84) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 77 (63.64%) | 5.53% |
| Reviews | 8 (6.61%) | 6.00% |
| Case Studies | 2 (1.65%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 34 (28.10%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multiple Dose Comparison of 18 µg, 36 µg of Ba679BR (Tiotropium) Inhalation Capsules and Oxitropium Metered Dose Inhaler (2 Puffs of 100µg) in a 4-week, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary [NCT02172807] | Phase 3 | 201 participants (Actual) | Interventional | 2000-12-31 | Completed | ||
| A Phase III Long-term Study of Ba253BINEB in Patients With COPD [NCT02182635] | Phase 3 | 74 participants (Actual) | Interventional | 1998-08-31 | Completed | ||
| Postmarketing Surveillance Study (as Per § 67(6) AMG [German Drug Law]) of Ventilat® Metered-dose Inhaler in Chronic Obstructive Bronchitis [NCT02233920] | 716 participants (Actual) | Observational | 2000-01-31 | Completed | |||
| A Phase III Study of Ba253BINEB in Patients With COPD - Double-blind, Randomised, Double Dummy, Multiple Dose Study in Comparison With MDI [NCT02182583] | Phase 3 | 163 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Phase III Long-term Study of Ba253BINEB in Patients With Bronchial Asthma [NCT02182661] | Phase 3 | 88 participants (Actual) | Interventional | 1998-07-31 | Completed | ||
| Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease [NCT02233907] | 595 participants (Actual) | Observational | 1999-10-31 | Completed | |||
| Agreement of Transcutaneous Partial Oxygen and Carbon Dioxide Pressure With Arterial and Capillary Blood Gas Values. A Single Centre Prospective Non-randomized Trial in Critically Ill Neonates. [NCT03060018] | 113 participants (Actual) | Interventional | 2017-08-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||